Cargando…
Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy
Small cell lung cancers (SCLCs) rapidly resist cytotoxic chemotherapy and immune checkpoint inhibitor (ICI) treatments. New, non-cross-resistant therapies are thus needed. SCLC cells are committed into neuroendocrine lineage then maturation arrested. Implicating DNA methyltransferase 1 (DNMT1) in th...
Autores principales: | Biswas, Sudipta, Kang, Kai, Ng, Kwok Peng, Radivoyevitch, Tomas, Schalper, Kurt, Zhang, Hua, Lindner, Daniel J., Thomas, Anish, MacPherson, David, Gastman, Brian, Schrump, David S., Kwok-Kin, Wong, Velcheti, Vamsidhar, Saunthararajah, Yogen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528072/ https://www.ncbi.nlm.nih.gov/pubmed/37597186 http://dx.doi.org/10.1016/j.celrep.2023.113016 |
Ejemplares similares
-
Novel pharmacologic approach to enhance the epigenetic and immune priming effect of decitabine in patients with advanced non-small cell lung cancer
por: Velcheti, Vamsidhar, et al.
Publicado: (2015) -
The current state of the art and future trends in RAS-targeted cancer therapies
por: Punekar, Salman R., et al.
Publicado: (2022) -
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017) -
High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects
por: Ebrahem, Quteba, et al.
Publicado: (2012) -
Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation
por: Ng, K P, et al.
Publicado: (2013)